Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
VR506
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion:
- Written informed consent
- Adolescents aged 12-17 years & adults aged 18-65 years (both inclusive)
- Documented clinical history of severe asthma requiring prednisone/prednisolone therapy, high-intensity treatment ICS, OCS, LABA
- Stable OCS dose for ≥7 days before Screening Visit & during Screening Period.
- At least 80% compliant w/regular asthma medication per investigator at end of Screening Period
- Documented asthma reversibility within 5 yrs prior to/during Screening Period, or diagnosis of asthma that is incontrovertible per investigator
- Ability to use nDPI correctly, per investigator's review of completed inhaler operation checklist
- Ability to use eDiary correctly, assessed by investigator at end of Screening Period
- Ability to comply w/study procedures, including blood sampling
- Ability to perform technically satisfactory pulmonary function tests
- Available to complete all study visits before 12 noon
- BMI of 16-26 kg/m2 in adolescents and 18-32 kg/m2 in adults
- Oral PIF ≥40 L/min, using an appropriate device set to match resistance of inhaler
- Good health, except for presence of asthma, per medical history/physical examination
- Negative drug/alcohol/urine cotinine screen. Subjects must test negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, ethanol & opiates (unless given as prescription medicine)
- Non-smokers or ex-smokers with a smoking history of less than 10 pack-yrs (e.g. <20 cigarettes per day for 10 years or <40 cigarettes per day for 5 years) & stopped smoking for at least 1 year prior to Screening Visit. Smoking will not be permitted throughout study
- Female subjects of child-bearing potential must be using medically acceptable forms of contraception [abstinence, hormonal (oral/implant/transdermal/injection), in use for ≥3 consecutive months before first dose of study medication, double barrier (condom w/spermicide, or diaphragm w/spermicide), IUD, or vasectomised partner (≥6 months since vasectomy)].
Exclusion:
- Regular use (≥3 times/wk) of topical steroids to treat dermatitis/rhinitis/allergic conjunctivitis, within 28 days of Screening Visit
- Subjects who have/who have had, an upper/lower respiratory tract infection within 28 days of Screening Visit
- Subjects w/"brittle asthma
- Subjects w/asthma that required admission to an ICU and/or ventilation within previous 12 months
- Subjects whose comorbidities, per investigator's opinion, are major contributors to their respiratory symptoms (e.g. COPD, bronchiectasis, dysfunctional breathlessness, vocal cord dysfunction, gastro-oesophageal reflux)
- Previously/currently diagnosed as having Churg-Strauss syndrome
- Previously/currently diagnosed as having pulmonary eosinophilia
- History of lung cancer
- Subjects w/current diagnosis of HIV infection
- Active chronic hepatitis B or C infection
- Subjects who have clinically significant abnormality/finding from examination, tests, or history that may compromise subject safety, specifically any history of cardiac, renal or hepatic impairment
- Subjects with an abnormal ECG
- Persistent arterial hypotension, with average SBP readings of ≤95 mmHg
- Persistent elevation of blood pressure, with average SBP readings of ≥160 mmHg or average DBP readings of ≥100 mmHg
- Pregnant or lactating females
- Participation in another clinical study in 28 days prior to Screening Visit
- Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrectable hypokalaemia, or predisposition to low levels of serum potassium
- Current/history of drug/alcohol abuse/dependence per WHO criteria
- Inability to communicate well w/investigator
- Donation of ≥450 mL of blood/blood products within previous 3 months prior to screening
- History of allergy/intolerance/contraindications to corticosteroids/lactose, or severe allergy to milk proteins
- Consumption of alcohol- or caffeine-containing foods/beverages from midnight before or during Screening Visit
- History of medically diagnosed chronic respiratory diseases other than asthma (e.g. chronic obstructive pulmonary disease, ABPA in the absence of asthma)
Sites / Locations
- Vectura Clinical Trial Site 01001
- Vectura Clinial Trial Site 01005
- Vectura Clinical Trial Site 01006
- Vectura Clinical Trial Site 01015
- Vectura Clinical Trial Site 01012
- Vectura Clinical Trial Site 01014
- Vectura Clinical Trial Site 01003
- Vectura Clinical Trial Site 01011
- Vectura Clinical Trial Site 01013
- Vectura Clinical Trial Site 01004
- Vectura Clinical Trial Site 01007
- Vectura Clinical Trial Site 08006
- Vectura Clinical Trial Site 08005
- Vectura Clinical Trial Site 08001
- Vectura Clinical Trial Site 08003
- Vectura Clinical Trial Site 08007
- Vectura Clinical Trial Site 08004
- Vectura Clinical Trial Site 08002
- Vectura Clinical Trial Site 08008
- Vectura Clinical Trial Site 03006
- Vectura Clinical Trial Site 03009
- Vectura Clinical Trial Site 03004
- Vectura Clinical Trial Site 03008
- Vectura Clinical Trial Site 03003
- Vectura Clinical Trial Site 03007
- Vectura Clinical Trial Site 03001
- Vectura Clinical Trial Site 03005
- Vectura Clinical Trial Site 03002
- Vectura Clinical Trial Site 04001
- Vectura Clinical Trial Site 04004
- Vectura Clinical Trial Site 04003
- Vectura Clinical Trial Site 04002
- Vectura Clinical Trial Site 04005
- Vectura Clinical Trial Site 05008
- Vectura Clinical Trial Site 05002
- Vectura Clinical Trial Site 05010
- Vectura Clinical Trial Site 05011
- Vectura Clinical Trial Site 05001
- Vectura Clinical Trial Site 05006
- Vectura Clinical Trial Site 05005
- Vectura Clinical Trial Site 05007
- Vectura Clinical Trial Site 05003
- Vectura Clinical Trial Site 05009
- Vectura Clinical Trial Site 05004
- Vectura Clinical Trial Site 07001
- Vectura Clinical Trial Site 07008
- Vectura Clinical Trial Site 07005
- Vectura Clinical Trial Site 07013
- Vectura Clinical Trial Site 07003
- Vectura Clinical Trial Site 07006
- Vectura Clinical Trial Site 07007
- Vectura Clinical Trial Site 07009
- Vectura Clinical Trial Site 07010
- Vectura Clinical Trial Site 07014
- Vectura Clinical Trial Site 07002
- Vectura Clinical Trial Site 07004
- Vectura Clinical Trial Site 07012
- Vectura Clinicl Trial Site 07011
- Vectura Clinical Trial Site 06013
- Vectura Clinical Trial Site 06009
- Vectura Clinical Trial Site 06012
- Vectura Clinical Trial Site 06010
- Vectura Clinical Trial Site 06001
- Vectura Clinical Trial Site 06004
- Vectura Clinical Trial Site 06006
- Vectura Clinical Trial Site 06002
- Vectura Clinical Trial Site 06015
- Vectura Clinical Trial Site 06003
- Vectura Clinical Trial Site 06008
- Vectura Clinical Trial Site 06011
- Vectura Clinical Trial Site 06007
- Vectura Clinical Trial Site 06014
- Vectura Clinical Trial Site 02003
- Vectura Clinical Trial site 02002
- Vectura Clinical Trial Site 02004
- Vectura Clinical Trial Site 02001
- Vectura Clinical Trial Site 02005
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Dose 1 VR506
Dose 2 VR506
Dose 3 VR506
Arm Description
VR506 inhalation powder delivered via a new dry powder inhaler device
VR506 inhalation powder delivered via a new dry powder inhaler device
VR506 inhalation powder delivered via a new dry powder inhaler device
Outcomes
Primary Outcome Measures
Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16)
The mean asthma control prednisone/prednisolone dose at end of study (week 16)
Secondary Outcome Measures
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score
Change from baseline to end of study (week 16) in 5 item asthma control questionnaire (ACQ-5) mean total score (range 0 (better) to 6 (worse)). The mean total score is calculated as the mean for each subject at each visit of 5 questions, each scored from 0 (better) to 6 (worse).
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score
To measure the change from baseline to end of study for the weekly mean asthma night time symptom score, scored from 0 (not at all bothered) to 6 (severely bothered).
Number of Participants With Withdrawals Due to Worsening of Asthma
Assessment of Acceptability of the Device
Percentage of subjects that overall found it very easy or fairly easy to use the inhaler, based on inhaler acceptability questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01720069
Brief Title
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Official Title
A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vectura Limited
4. Oversight
5. Study Description
Brief Summary
To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily regimen from a new dry powder inhaler (nDPI) for 16 weeks in subjects with severe persistent asthma requiring OCS therapy, i.e. Step 5 treatment as defined by modified Global Initiative for Asthma (GINA) guidelines 2011.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
197 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dose 1 VR506
Arm Type
Active Comparator
Arm Description
VR506 inhalation powder delivered via a new dry powder inhaler device
Arm Title
Dose 2 VR506
Arm Type
Active Comparator
Arm Description
VR506 inhalation powder delivered via a new dry powder inhaler device
Arm Title
Dose 3 VR506
Arm Type
Active Comparator
Arm Description
VR506 inhalation powder delivered via a new dry powder inhaler device
Intervention Type
Drug
Intervention Name(s)
VR506
Intervention Description
VR506 inhalation powder delivered via a new dry powder inhaler device
Primary Outcome Measure Information:
Title
Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16)
Description
The mean asthma control prednisone/prednisolone dose at end of study (week 16)
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)
Time Frame
Baseline and 16 weeks
Title
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score
Description
Change from baseline to end of study (week 16) in 5 item asthma control questionnaire (ACQ-5) mean total score (range 0 (better) to 6 (worse)). The mean total score is calculated as the mean for each subject at each visit of 5 questions, each scored from 0 (better) to 6 (worse).
Time Frame
Baseline and 16 weeks
Title
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)
Time Frame
Baseline and 16 weeks
Title
Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score
Description
To measure the change from baseline to end of study for the weekly mean asthma night time symptom score, scored from 0 (not at all bothered) to 6 (severely bothered).
Time Frame
Baseline and 16 weeks
Title
Number of Participants With Withdrawals Due to Worsening of Asthma
Time Frame
16 weeks
Title
Assessment of Acceptability of the Device
Description
Percentage of subjects that overall found it very easy or fairly easy to use the inhaler, based on inhaler acceptability questionnaire
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion:
Written informed consent
Adolescents aged 12-17 years & adults aged 18-65 years (both inclusive)
Documented clinical history of severe asthma requiring prednisone/prednisolone therapy, high-intensity treatment ICS, OCS, LABA
Stable OCS dose for ≥7 days before Screening Visit & during Screening Period.
At least 80% compliant w/regular asthma medication per investigator at end of Screening Period
Documented asthma reversibility within 5 yrs prior to/during Screening Period, or diagnosis of asthma that is incontrovertible per investigator
Ability to use nDPI correctly, per investigator's review of completed inhaler operation checklist
Ability to use eDiary correctly, assessed by investigator at end of Screening Period
Ability to comply w/study procedures, including blood sampling
Ability to perform technically satisfactory pulmonary function tests
Available to complete all study visits before 12 noon
BMI of 16-26 kg/m2 in adolescents and 18-32 kg/m2 in adults
Oral PIF ≥40 L/min, using an appropriate device set to match resistance of inhaler
Good health, except for presence of asthma, per medical history/physical examination
Negative drug/alcohol/urine cotinine screen. Subjects must test negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, ethanol & opiates (unless given as prescription medicine)
Non-smokers or ex-smokers with a smoking history of less than 10 pack-yrs (e.g. <20 cigarettes per day for 10 years or <40 cigarettes per day for 5 years) & stopped smoking for at least 1 year prior to Screening Visit. Smoking will not be permitted throughout study
Female subjects of child-bearing potential must be using medically acceptable forms of contraception [abstinence, hormonal (oral/implant/transdermal/injection), in use for ≥3 consecutive months before first dose of study medication, double barrier (condom w/spermicide, or diaphragm w/spermicide), IUD, or vasectomised partner (≥6 months since vasectomy)].
Exclusion:
Regular use (≥3 times/wk) of topical steroids to treat dermatitis/rhinitis/allergic conjunctivitis, within 28 days of Screening Visit
Subjects who have/who have had, an upper/lower respiratory tract infection within 28 days of Screening Visit
Subjects w/"brittle asthma
Subjects w/asthma that required admission to an ICU and/or ventilation within previous 12 months
Subjects whose comorbidities, per investigator's opinion, are major contributors to their respiratory symptoms (e.g. COPD, bronchiectasis, dysfunctional breathlessness, vocal cord dysfunction, gastro-oesophageal reflux)
Previously/currently diagnosed as having Churg-Strauss syndrome
Previously/currently diagnosed as having pulmonary eosinophilia
History of lung cancer
Subjects w/current diagnosis of HIV infection
Active chronic hepatitis B or C infection
Subjects who have clinically significant abnormality/finding from examination, tests, or history that may compromise subject safety, specifically any history of cardiac, renal or hepatic impairment
Subjects with an abnormal ECG
Persistent arterial hypotension, with average SBP readings of ≤95 mmHg
Persistent elevation of blood pressure, with average SBP readings of ≥160 mmHg or average DBP readings of ≥100 mmHg
Pregnant or lactating females
Participation in another clinical study in 28 days prior to Screening Visit
Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrectable hypokalaemia, or predisposition to low levels of serum potassium
Current/history of drug/alcohol abuse/dependence per WHO criteria
Inability to communicate well w/investigator
Donation of ≥450 mL of blood/blood products within previous 3 months prior to screening
History of allergy/intolerance/contraindications to corticosteroids/lactose, or severe allergy to milk proteins
Consumption of alcohol- or caffeine-containing foods/beverages from midnight before or during Screening Visit
History of medically diagnosed chronic respiratory diseases other than asthma (e.g. chronic obstructive pulmonary disease, ABPA in the absence of asthma)
Facility Information:
Facility Name
Vectura Clinical Trial Site 01001
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Vectura Clinial Trial Site 01005
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Vectura Clinical Trial Site 01006
City
Celebration
State/Province
Florida
ZIP/Postal Code
34747
Country
United States
Facility Name
Vectura Clinical Trial Site 01015
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33018
Country
United States
Facility Name
Vectura Clinical Trial Site 01012
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Vectura Clinical Trial Site 01014
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Vectura Clinical Trial Site 01003
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Vectura Clinical Trial Site 01011
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110-1093
Country
United States
Facility Name
Vectura Clinical Trial Site 01013
City
Jersey City
State/Province
New Jersey
ZIP/Postal Code
07306
Country
United States
Facility Name
Vectura Clinical Trial Site 01004
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Vectura Clinical Trial Site 01007
City
El Paso
State/Province
Texas
ZIP/Postal Code
79925
Country
United States
Facility Name
Vectura Clinical Trial Site 08006
City
Ruse
ZIP/Postal Code
7000
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08005
City
Sofia
ZIP/Postal Code
1000
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08001
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08003
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08007
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08004
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08002
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 08008
City
Varna
ZIP/Postal Code
9000
Country
Bulgaria
Facility Name
Vectura Clinical Trial Site 03006
City
Berlin
ZIP/Postal Code
10717
Country
Germany
Facility Name
Vectura Clinical Trial Site 03009
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Facility Name
Vectura Clinical Trial Site 03004
City
Bonn
ZIP/Postal Code
53119
Country
Germany
Facility Name
Vectura Clinical Trial Site 03008
City
Donaustauf
ZIP/Postal Code
93093
Country
Germany
Facility Name
Vectura Clinical Trial Site 03003
City
Dortmund
ZIP/Postal Code
44263
Country
Germany
Facility Name
Vectura Clinical Trial Site 03007
City
Geesthacht
ZIP/Postal Code
21502
Country
Germany
Facility Name
Vectura Clinical Trial Site 03001
City
Hamburg
ZIP/Postal Code
22767
Country
Germany
Facility Name
Vectura Clinical Trial Site 03005
City
Heidelberg
ZIP/Postal Code
69126
Country
Germany
Facility Name
Vectura Clinical Trial Site 03002
City
Rudersdorf
ZIP/Postal Code
15562
Country
Germany
Facility Name
Vectura Clinical Trial Site 04001
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Facility Name
Vectura Clinical Trial Site 04004
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Vectura Clinical Trial Site 04003
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Vectura Clinical Trial Site 04002
City
Rakoczi
ZIP/Postal Code
125 127
Country
Hungary
Facility Name
Vectura Clinical Trial Site 04005
City
Rakoczi
ZIP/Postal Code
7100
Country
Hungary
Facility Name
Vectura Clinical Trial Site 05008
City
Bialystok
ZIP/Postal Code
15-003
Country
Poland
Facility Name
Vectura Clinical Trial Site 05002
City
Bialystok
ZIP/Postal Code
15-276
Country
Poland
Facility Name
Vectura Clinical Trial Site 05010
City
Bialystok
ZIP/Postal Code
15-430
Country
Poland
Facility Name
Vectura Clinical Trial Site 05011
City
Krakow
ZIP/Postal Code
31-024
Country
Poland
Facility Name
Vectura Clinical Trial Site 05001
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Vectura Clinical Trial Site 05006
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Vectura Clinical Trial Site 05005
City
Lublin
ZIP/Postal Code
20-552
Country
Poland
Facility Name
Vectura Clinical Trial Site 05007
City
Tarnow
ZIP/Postal Code
33-100
Country
Poland
Facility Name
Vectura Clinical Trial Site 05003
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland
Facility Name
Vectura Clinical Trial Site 05009
City
Wroclaw
ZIP/Postal Code
51-162
Country
Poland
Facility Name
Vectura Clinical Trial Site 05004
City
Zawadzkie
ZIP/Postal Code
47-120
Country
Poland
Facility Name
Vectura Clinical Trial Site 07001
City
Brasov
ZIP/Postal Code
500086
Country
Romania
Facility Name
Vectura Clinical Trial Site 07008
City
Bucuresti
ZIP/Postal Code
010457
Country
Romania
Facility Name
Vectura Clinical Trial Site 07005
City
Bucuresti
ZIP/Postal Code
020671
Country
Romania
Facility Name
Vectura Clinical Trial Site 07013
City
Bucuresti
ZIP/Postal Code
030303
Country
Romania
Facility Name
Vectura Clinical Trial Site 07003
City
Bucuresti
ZIP/Postal Code
050554
Country
Romania
Facility Name
Vectura Clinical Trial Site 07006
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
Facility Name
Vectura Clinical Trial Site 07007
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
Facility Name
Vectura Clinical Trial Site 07009
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
Facility Name
Vectura Clinical Trial Site 07010
City
Cod
ZIP/Postal Code
700115
Country
Romania
Facility Name
Vectura Clinical Trial Site 07014
City
Craiova
ZIP/Postal Code
200515
Country
Romania
Facility Name
Vectura Clinical Trial Site 07002
City
Iasi
ZIP/Postal Code
700376
Country
Romania
Facility Name
Vectura Clinical Trial Site 07004
City
Marghita
ZIP/Postal Code
415300
Country
Romania
Facility Name
Vectura Clinical Trial Site 07012
City
Targu Mures
ZIP/Postal Code
540543
Country
Romania
Facility Name
Vectura Clinicl Trial Site 07011
City
Timis
ZIP/Postal Code
300310
Country
Romania
Facility Name
Vectura Clinical Trial Site 06013
City
AR Crimea
ZIP/Postal Code
97403
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06009
City
Donetsk
ZIP/Postal Code
83099
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06012
City
Ivano-Frankivsk
ZIP/Postal Code
76018
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06010
City
Kharkiv
ZIP/Postal Code
61002
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06001
City
Kharkiv
ZIP/Postal Code
61035
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06004
City
Kharkiv
ZIP/Postal Code
61106
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06006
City
Kyiv
ZIP/Postal Code
02232
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06002
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06015
City
Kyiv
ZIP/Postal Code
3680
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06003
City
Kyviv
ZIP/Postal Code
04050
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06008
City
Mykolaiv
ZIP/Postal Code
54003
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06011
City
Vinnitsa
ZIP/Postal Code
21029
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06007
City
Zaporizhzhia
ZIP/Postal Code
69600
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 06014
City
Zaporizhzhya
ZIP/Postal Code
69118
Country
Ukraine
Facility Name
Vectura Clinical Trial Site 02003
City
Cottingham
State/Province
Hull
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
Vectura Clinical Trial site 02002
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Facility Name
Vectura Clinical Trial Site 02004
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Vectura Clinical Trial Site 02001
City
Newcastle
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
Vectura Clinical Trial Site 02005
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
We'll reach out to this number within 24 hrs